phrykt

In8Bio, Inc. (INAB): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of INAB were reported in the last 12 months. 2 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

No INAB insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

INAB short interest

Low short interest. 0.2% of INAB shares are sold short: about 1 share in 627. Over the last 12 reports the number of shares short went down 90%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 15,733 INAB shares were sold short, 0.2% of the shares outstanding, down 52.0% from the report before. At the average daily volume of 36,207 shares, buying them all back would take about 1.0 trading days (days to cover).

Shares short, % of all shares

0.16%May 15Oct 301.87%

Days to cover

1.0May 15Oct 303.4

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202615,7330.16%-52%36,2071.0
Oct 15, 202632,7970.33%-29%46,3951.0
Sep 30, 202646,4400.47%-26%53,4881.0
Sep 15, 202663,1100.64%-31%28,6162.2
Aug 31, 202690,8420.92%-35%55,2951.6
Aug 14, 2026139,9031.42%+462%98,4391.4
Jul 31, 202624,9130.25%+20%55,3861.0
Jul 15, 202620,7890.21%-41%53,2831.0
Jun 30, 202635,1170.36%-24%37,4971.0
Jun 15, 202645,9070.47%-57%55,7641.0
May 29, 2026107,4161.09%-34%82,5831.3
May 15, 2026161,8131.64%-34%52,2503.1

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

In8Bio company events

In8Bio filed 9 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Aug 6, 2026ResultsReleased financial results. Filing
  3. Jun 1, 2026AgreementIN8bio, Inc. entered into a Capital on Demand TM Sales Agreement with JonesTrading Institutional Services LLC with respect to an at the market offering program under which the Company may issue and sell, from time to time at its sole discretion, shares of its common stock, par value $0.0001 per… Filing
  4. May 7, 2026LeadershipAs described in Item 5.07 below, on May 7, 2026, at the Company’s 2026 annual meeting of stockholders, the Company’s stockholders approved the Company’s Amended and Restated 2026 Equity Incentive Plan, which is the successor to the Company’s Amended and Restated 2023 Equity Incentive Plan. Filing
  5. Mar 12, 2026ResultsReleased financial results. Filing
  6. Feb 27, 2026LeadershipAlan S. Roemer notified the Board of Directors of IN8bio, Inc. of his decision to resign as a director of the Board and as a member of the Audit and Compensation Committees of the Board, effective as of February 28, 2026. Filing
  7. Feb 9, 2026LeadershipThe Company’s Board of Directors appointed Kate Rochlin, the Company’s Chief Operating Officer, as President of the Company, effective February 4, 2026. Filing
  8. Dec 19, 2025AgreementIN8bio, Inc. entered into a Securities Purchase Agreement with the purchasers named therein, pursuant to which the Company agreed to issue and sell shares of the Company’s common stock, par value $0.0001 per share, and, in lieu of Common Stock, pre-funded warrants (the “Pre-Funded Warrants” and… Filing
  9. Nov 24, 2025AnnouncementIN8bio, Inc. presented consolidated data, a summary of which is located below, from its investigator-sponsored Phase 1 single-center clinical trial of INB-200 and its Company-sponsored Phase 2 multi-center clinical trial of INB-400 for the treatment of patients with newly diagnosed glioblastoma in… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

In8Bio financials

Famous investors that hold INAB

2 of the 50 well-known investors we track reported holding INAB in their latest 13F filing. The largest position is Jim Simons's, worth $45.1K.

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 202633,917$45.1K0.0%+180%
Ken Griffin · Citadel AdvisorsQ3 202622,984$30.6K0.0%-64%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about In8Bio, Inc. (INAB) stock

Are INAB insiders buying or selling?

No INAB insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in INAB?

As of Oct 30, 2026, 15,733 INAB shares were sold short, 0.2% of the shares outstanding, down 52.0% from the report before. At the average daily volume of 36,207 shares, buying them all back would take about 1.0 trading days (days to cover). See the history.

Which famous investors hold INAB?

2 of the 50 well-known investors we track reported INAB in their latest 13F filing, including Jim Simons, Ken Griffin. The largest position is worth $45.1K. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.